Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Webcasts
  • Français
  • my CNW 
    • Login
    • Register
  • Client Login
  • Sign Up
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.

News Releases

view all
    Advanced Search
    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Canadian Federal Government
        • Canadian Municipal Government
        • Canadian Provincial Government
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Advanced Search
    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • IR
    • All Products
    • Become a Client
    • Request a Demo
    • Editorial Bureaus
    • Partnerships
    • General Enquiries
    • Media
    • Worldwide Offices
    • Hamburger menu
    • Cision Canada
    • Send a Release
    • FR
      • Phone

      • 877-269-7890 from 8 AM - 10 PM ET

      • ALL CONTACT INFO
      • Contact Cision

        877-269-7890
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Sign Up
      • Resources
      • Investor Relations
      • Journalists
      • Webcasts
      • my CNW
      • GDPR
      • 3 News in Focus
      • 5 Business
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Sign Up
      • Resources
      • Investor Relations
      • Journalists
      • Webcasts
      • my CNW
      • GDPR
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • IR
      • All Products
      • Send a Release
      • Sign Up
      • Resources
      • Investor Relations
      • Journalists
      • Webcasts
      • my CNW
      • GDPR
      • Become a Client
      • Request a Demo
      • Editorial Bureaus
      • Partnerships
      • General Enquiries
      • Media
      • Worldwide Offices
      • General Enquiries
      • Send a Release
      • Sign Up
      • Resources
      • Investor Relations
      • Journalists
      • Webcasts
      • my CNW
      • GDPR
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business) Business
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      HLS Therapeutics Announces Q2 2025 Financial Results


      News provided by

      HLS Therapeutics Inc.

      Aug 14, 2025, 06:31 ET

      Share this article

      Share this article


      • Adjusted EBITDA grew 21% in Q2 and 29% year-to-date
      • Cash from operations grew 83% in Q2 and 147% year-to-date
      • Made principal repayments on the Company's long-term debt totalling $8.5 million
      • Expanded cardiovascular portfolio by licensing Canadian rights to NEXLETOL® and NEXLIZET® from Esperion Therapeutics

      TORONTO, Aug. 14, 2025 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focused on addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease, announces its financial results for the three and six months ended June 30, 2025 ("Q2 2025" and "year-to-date"). All amounts are in thousands of United States ("U.S.") dollars unless otherwise stated.

      Q2 & YEAR-TO-DATE 2025 FINANCIAL HIGHLIGHTS (comparisons are to the respective 2024 periods)

      • Q2 2025 revenue was $14.2 million, Adjusted EBITDA1 was $5.2 million and cash from operations was $4.6 million, compared to $14.5 million, $4.3 million and $2.5 million, respectively.
      • Year-to-date 2025 revenue was $26.8 million, Adjusted EBITDA was $9.0 million and cash from operations was $8.1 million, compared to $27 million, $7 million and $3.3 million, respectively.
      • In local currency, combined Canadian product sales for Vascepa and Clozaril were flat in Q2 2025 and were up 6% year-to-date.
      • US sales of Clozaril were up 1% in Q2 2025 and were up 2% year-to-date.
      • Excluding cost of sales, operating expenses decreased 18% in Q2 2025 and 19% year-to-date.
      • Vascepa made a positive contribution to Adjusted EBITDA in Q2 2025 for the third straight quarter.

      Q2 2025 CORPORATE HIGHLIGHTS

      • Announced in-license agreement with Esperion Therapeutics Inc. (NASDAQ:ESPR) to commercialize NEXLETOL2 and NEXLIZET2 in Canada.
      • Made principal repayments on the Company's long-term debt totalling $8.5 million.
      • Repurchased $0.8 million of common stock in Q2 2025. Year-to-date, the Company has purchased $1.0 million of common stock at an average price of C$4.56 per share.

      "Our year-to-date results reflect continued execution on our key strategic priorities as we position the Company to resume its growth trajectory," said Craig Millian, Chief Executive Officer at HLS. "We remain on track to achieve full-year guidance, with strong underlying performance demonstrated by 29% year-to-date Adjusted EBITDA growth, robust cash flow generation, and continued balance sheet strengthening through significant debt repayments."

      "Looking ahead, we're excited to introduce NEXLETOL and NEXLIZET in Canada, addressing an important treatment need for at-risk Canadian patients. These medicines have the potential to more than double the size of our cardiovascular business and will further establish HLS as a leading Canadian-based company focused on cardiovascular risk reduction. With Health Canada approval expected by year-end and launch planned for Q2 2026, we believe HLS is well-positioned for our next phase of growth."

      Q2 & YEAR-TO-DATE 2025 FINANCIAL REVIEW
      The Company's Management's Discussion and Analysis and Consolidated Financial Statements for the three and six months ended June 30, 2025, are available at the Company's website and at its profile at SEDAR+.

      Revenue


      Three months ended

      June 30,

      Six months ended

      June 30,


      2025

      2024

      2025

      2024






      Product sales





         Canada

      10,521

      10,637

      20,229

      19,791

       United States

      3,502

      3,462

      6,220

      6,104


      14,023

      14,099

      26,449

      25,895

      Royalty revenue

      148

      420

      345

      1,097


      14,171

      14,519

      26,794

      26,992

      Revenue for Q2 2025 decreased 2%, due primarily to lower royalty revenues and FX rate fluctuations. Year-to-date 2025, revenue was essentially flat with 2% growth in product revenue being offset by a 69% drop in royalty revenue.

      Product sales – Canada

      000's of CAD

      Three months ended

      June 30,

      Six months ended

      June 30,


      2025

      2024

      % change

      2025

      2024

      % change








      Clozaril

      8,589

      9,131

      (5.9) %

      16,518

      16,996

      (2.8) %

      Vascepa

      5,884

      5,407

      8.8 %

      11,862

      9,878

      20.1 %

      Other

      76

      14


      108

      27



      14,549

      14,552

      0.0 %

      28,488

      26,901

      5.9 %

      Canadian product sales in local currency were flat in Q2 2025 and up 6% year-to-date, compared to the same periods last year. The Q2 2024 period benefited from the timing of certain orders shifting from Q1 2024 because of the Easter holiday timing last year. For this reason, the Company views year-to-date revenue as a more relevant measure for the comparison of year-over-year revenue performance.

      Product Sales – United States

      In the U.S. market, Clozaril revenue for the three and six months ended June 30, 2025, increased 1% and 2%, respectively, compared to the same prior year periods.

      Royalty revenues

      As expected, following the sale of the Xenpozyme royalty interest in Q2 2024, royalty revenue has declined. Royalty revenue for the three and six months ended June 30, 2025, was down 65% and 69%, respectively, compared to the same periods last year. HLS has one remaining royalty interest which generated $0.15 million in revenue in Q2 2025.

      Operating Expenses


      Three months ended

      June 30,

      Six months ended

      June 30,


      2025

      2024

      2025

      2024






      Cost of product sales

      2,505

      2,303

      4,903

      4,077

      Selling and marketing

      3,046

      4,561

      5,876

      9,087

      Medical, regulatory and patient support

      1,366

      1,420

      2,802

      2,685

      General and administrative

      2,084

      1,977

      4,223

      4,178


      9,001

      10,261

      17,804

      20,027

      Cost of product sales increased for the three and six months ended June 30, 2025, due primarily to higher Vascepa sales volumes.

      Operating expenses in Q2 2025, excluding cost of product sales, decreased by 18% compared to Q2 2024, and by 19% for the year-to-date period. This was primarily due to lower selling and marketing expenses following the Company's discontinuation of co-promotional activities with its marketing partner in August 2024. While selling and marketing expenses will remain below 2024 levels throughout the year, quarterly selling and marketing expenses are expected to be moderately higher for the remainder of 2025 as several staff vacancies have now been filled.

      Adjusted EBITDA1


      Three months ended

      June 30,

      Six months ended

      June 30,


      2025

      2024

      2025

      2024






      Net loss for the period

      (2,741)

      (5,682)

      (7,177)

      (11,788)

      Stock-based compensation

      465

      427

      1,116

      683

      Amortization and depreciation

      5,483

      5,856

      10,843

      11,775

      Finance and related costs, net

      1,690

      2,942

      3,662

      5,609

      Other costs

      31

      (3,361)

      327

      (3,361)

      Income tax expense

      242

      4,076

      219

      4,047

      Adjusted EBITDA

      5,170

      4,258

      8,990

      6,965

      Adjusted EBITDA for the three and six months ended June 30, 2025, increased 21% and 29%, respectively, compared to the same periods last year. The increases were primarily due to steady performance from the Company's marketed products and the ongoing focus on cost management and were partially offset by FX fluctuations and the previously mentioned decline in royalty revenue. Excluding royalty revenue, Adjusted EBITDA for the three and six months ended June 30, 2025, would have increased 31% and 47%, respectively, compared to the same periods last year.   

      In Q2 2025, the direct brand contribution from Clozaril to Adjusted EBITDA was $7.1 million, while the direct brand contribution from Vascepa to Adjusted EBITDA improved from negative $1.6 million in Q2 2024 to positive $0.1 million. Year-to-date, the direct brand contribution from Clozaril to Adjusted EBITDA was $12.9 million, while the direct brand contribution from Vascepa to Adjusted EBITDA improved from negative $3.2 million to positive $0.1 million.

      Net Loss
      Q2 2025 net loss was ($2.7) million, or ($0.09) per share, compared to a net loss of ($5.7) million, or ($0.18) per share, in Q2 2024. Year-to-date net loss was ($7.2) million, or ($0.23) per share, compared to a net loss of ($11.8) million, or ($0.37) per share, in the same period last year. Net loss improved in both periods of 2025 due primarily to the previously noted factors that have positively impacted Adjusted EBITDA this year.

      Cash from Operations and Financial Position
      Cash generated from operations for the three and six months ended June 30, 2025, was $4.6 million and $8.1 million, compared to $2.5 million and $3.3 million in the same periods last year. This represents year-over-year increases of 83% and 147%, respectively.

      Total borrowings under the credit agreement at June 30, 2025, were $56.0 million compared to $67.4 million at December 31, 2024, and $84.9 million at June 30, 2024. This represents a reduction of 34% from June 30, 2024.

      During Q2 2025, HLS made principal payments on its term loan totaling $8.5 million and spent $0.8 million to purchase shares for cancellation under its Normal Course Issuer Bid. Year-to-date, HLS has made debt principal repayments of $11.4 million and under its share buyback program, has purchased 308,928 shares at a cost of $1 million since launching the buyback on March 17, 2025.

      Cash was $12.2 million at June 30, 2025, compared to $17.5 million at December 31, 2024. The decrease reflects the debt principal repayments, and the share buyback activity described previously, offset, in part, by the significant increase in cash from operations.

      2025 OUTLOOK
      Revenue projections for the Company's Canadian product portfolio are denominated in local currency to account for ongoing FX rate fluctuations.

      2025 financial targets are unchanged and as follows:

      • Vascepa revenue of C$26.5-28.5 million (18-26% growth)
      • Canada Clozaril sales of C$35.5-36 million (flat year-over-year)
      • U.S. Clozaril sales of $12-12.3 million (2-4% decline)
      • Royalty revenue of $0.6-0.75 million (50-60% decline)
      • Consolidated Adjusted EBITDA of $19.5-20.5 million (17-23% growth)

      Future results could be impacted by continued exchange rate volatility.

      Q2 2025 CONFERENCE CALL
      HLS will hold a conference call today at 8:30 am Eastern Time to discuss its Q2 and year-to-date 2025 financial results. The call will be hosted by Mr. Craig Millian, CEO, Mr. John Hanna, CFO and Mr. Brian Walsh, CCO. To view the slides that accompany management's discussion, please use the webcast link.

      CONFERENCE ID: 66543

      DATE: Thursday, August 14, 2025

      TIME: 8:30 a.m. ET

      WEBCAST LINK: https://app.webinar.net/Zo9wjb9V5KR       

      TRADITIONAL DIAL-IN NUMBER: 1-888-699-1199 or 1-416-945-7677

      RAPIDCONNECT: To instantly join the conference call by phone, please use the following URL to easily register and be connected into the conference call automatically: https://emportal.ink/4kiYlSu 

      TAPED REPLAY:  1-888-660-6345 or 1-289-819-1450

      REPLAY CODE: 66543#

      The taped replay will be available for 14 days and the archived webcast will be available for 365 days.

      A link to the live audio webcast of the conference call will also be available on the events page of the investors section of HLS Therapeutics' website at www.hlstherapeutics.com. Please connect at least 15 minutes before the conference call to ensure enough time for any software download required to hear the webcast.

      ABOUT HLS THERAPEUTICS INC.
      Formed in 2015, HLS is a pharmaceutical company focused on the acquisition and commercialization of late-stage development, commercial stage promoted and established branded pharmaceutical products in the North American markets. HLS's focus is on products targeting the central nervous system and cardiovascular therapeutic areas. HLS's management team is composed of seasoned pharmaceutical executives with a strong track record of success in these therapeutic areas and at managing products in each of these lifecycle stages. For more information visit: www.hlstherapeutics.com

      1CAUTIONARY NOTE REGARDING NON-IFRS MEASURES
      This press release refers to certain non-IFRS measures. These measures are not recognized measures under IFRS, do not have a standardized meaning prescribed by IFRS and are therefore unlikely to be comparable to similar measures presented by other companies. Rather, these measures are provided as additional information to complement those IFRS measures by providing further understanding of HLS's results of operations from management's perspective. Accordingly, they should not be considered in isolation nor as a substitute for analysis of HLS's financial information reported under IFRS. HLS uses non-IFRS measures to provide investors with supplemental measures of its operating performance and thus highlight trends in its core business that may not otherwise be apparent when relying solely on IFRS financial measures. HLS also believes that securities analysts, investors and other interested parties frequently use non-IFRS measures in the evaluation of issuers. HLS's management also uses non-IFRS measures in order to facilitate operating performance comparisons from period to period, prepare annual operating budgets and assess HLS's ability to meet its future debt service, capital expenditure and working capital requirements.

      In particular, management uses Adjusted EBITDA as a measure of HLS's performance.  To reconcile net income (loss) for the period with Adjusted EBITDA, each of (i) "stock-based compensation", (ii) "amortization and depreciation", (iii) "finance and related costs, net", (iv) "other costs (income)", and (v) "income tax expense (recovery)" appearing in the Consolidated Statement of Net Income (Loss) are added to net income (loss) for the period to determine Adjusted EBITDA. Adjusted EBITDA does not have any standardized meaning prescribed by IFRS and is not necessarily comparable to similar measures presented by other companies.  Adjusted EBITDA should not be considered in isolation or as a substitute for net income (loss) prepared in accordance with IFRS as issued by the IASB.

      REFERENCES
      2: NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) are the commercial brand names in the U.S. The brand names in Canada are to be confirmed upon approval by Health Canada.

      FORWARD LOOKING INFORMATION
      This release includes forward-looking statements regarding HLS and its business. Such statements are based on the current expectations and views of future events of HLS's management. In some cases the forward-looking statements can be identified by words or phrases such as "may", "will", "expect", "plan", "anticipate", "intend", "potential", "estimate", "believe" or the negative of these terms, or other similar expressions intended to identify forward-looking statements, including, among others, statements with respect to HLS's pursuit of additional product and pipeline opportunities in certain therapeutic markets, statements regarding growth opportunities, expectations regarding financial performance, and the NCIB and ASPP. The forward-looking events and circumstances discussed in this release may not occur and could differ materially as a result of known and unknown risk factors and uncertainties affecting HLS, including risks relating to the specialty pharmaceutical industry, risks related to the regulatory approval process, economic factors and many other factors beyond the control of HLS. Forward-looking statements and information by their nature are based on assumptions and involve known and unknown risks, uncertainties and other factors which may cause HLS's actual results, performance or achievements, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statement or information. Accordingly, readers should not place undue reliance on any forward-looking statements or information. A discussion of the material risks and assumptions associated with this release can be found in the Company's Annual Information Form dated March 12, 2025, and Management's Discussion and Analysis dated August 13, 2025, both of which have been filed on SEDAR+ and can be accessed at www.sedarplus.ca. Accordingly, readers should not place undue reliance on any forward-looking statements or information. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and HLS undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise.

      HLS THERAPEUTICS INC.

      INTERIM CONSOLIDATED STATEMENTS OF FINANCIAL POSITION

      Unaudited

      [in thousands of U.S. dollars]






      As at

      As at



      June 30, 2025

      December 31, 2024





      ASSETS




      Current




      Cash


      12,153

      17,456

      Accounts receivable


      8,968

      7,454

      Inventories


      6,823

      9,058

      Income taxes recoverable


      80

      71

      Other current assets


      2,011

      1,361

      Total current assets


      30,035

      35,400

      Property, plant and equipment


      1,048

      997

      Intangible assets


      116,047

      122,122

      Deferred tax asset


      1,386

      857

      Other non-current assets


      556

      528

      Total assets


      149,072

      159,904





      LIABILITIES AND SHAREHOLDERS' EQUITY


      Current




      Accounts payable and accrued liabilities


      8,339

      8,709

      Provisions


      11,814

      8,367

      Debt and other liabilities


      7,025

      5,317

      Income taxes payable


      411

      152

      Total current liabilities


      27,589

      22,545

      Debt and other liabilities


      50,799

      61,944

      Deferred tax liability


      4,125

      4,074

      Total liabilities


      82,513

      88,563





      Shareholders' equity




      Share capital


      258,063

      260,595

      Contributed surplus


      14,788

      15,136

      Accumulated other comprehensive loss


      (6,458)

      (10,210)

      Deficit


      (199,834)

      (194,180)

      Total shareholders' equity


      66,559

      71,341

      Total liabilities and shareholders' equity


      149,072

      159,904





      HLS THERAPEUTICS INC.

      INTERIM CONSOLIDATED STATEMENTS OF LOSS

      Unaudited

      [in thousands of U.S. dollars, except per share amounts]




      Three months ended

      June 30,

      Six months ended

      June 30,



      2025

      2024

      2025

      2024







      Revenue


      14,171

      14,519

      26,794

      26,992







      Expenses






      Cost of product sales


      2,505

      2,303

      4,903

      4,077

      Selling and marketing


      3,046

      4,561

      5,876

      9,087

      Medical, regulatory and patient support


      1,366

      1,420

      2,802

      2,685

      General and administrative


      2,084

      1,977

      4,223

      4,178

      Stock-based compensation


      465

      427

      1,116

      683

      Amortization and depreciation


      5,483

      5,856

      10,843

      11,775

      Finance and related costs, net


      1,690

      2,942

      3,662

      5,609

      Other costs (income)


      31

      (3,361)

      327

      (3,361)

      Loss before income taxes


      (2,499)

      (1,606)

      (6,958)

      (7,741)

      Income tax expense


      242

      4,076

      219

      4,047

      Net loss for the period


      (2,741)

      (5,682)

      (7,177)

      (11,788)





      Net loss per share:




      Basic and diluted


      $(0.09)

      $(0.18)

      $(0.23)

      $(0.37)




      HLS THERAPEUTICS INC.

      INTERIM CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS

      Unaudited

      [in thousands of U.S. dollars]




      Three months ended

      June 30,

      Six months ended

      June 30,


      2025

      2024

      2025

      2024






      Net loss for the period

      (2,741)

      (5,682)

      (7,177)

      (11,788)






      Item that may be reclassified subsequently to net loss





         Unrealized foreign currency translation adjustment

      3,440

      (963)

      3,752

      (3,336)

      Comprehensive income (loss) for the period

      699

      (6,645)

      (3,425)

      (15,124)




      HLS THERAPEUTICS INC.

      INTERIM CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY

      Unaudited

      [in thousands of U.S. dollars]








      Share

      capital

      Contributed

      surplus

      Accumulated other
      comprehensive loss

      Deficit

      Total








      Balance as at December 31, 2024


      260,595

      15,136

      (10,210)

      (194,180)

      71,341

      Shares repurchased


      (2,532)

      —

      —

      1,523

      (1,009)

      Change in share purchase obligation


      —

      (878)

      —

      —

      (878)

      Stock option expense


      —

      530

      —

      —

      530

      Net loss for the period


      —

      —

      —

      (7,177)

      (7,177)

      Unrealized foreign currency    translation adjustment


      —

      —

      3,752

      —

      3,752

      Balance as at June 30, 2025


      258,063

      14,788

      (6,458)

      (199,834)

      66,559








      Balance as at December 31, 2023


      262,127

      13,865

      (2,838)

      (175,457)

      97,697

      Shares repurchased


      (1,532)

      —

      —

      932

      (600)

      Change in share purchase obligation


      —

      300

      —

      —

      300

      Stock option expense


      —

      433

      —

      —

      433

      Net loss for the period


      —

      —

      —

      (11,788)

      (11,788)

      Unrealized foreign currency    translation adjustment


      —

      —

      (3,336)

      —

      (3,336)

      Balance as at June 30, 2024


      260,595

      14,598

      (6,174)

      (186,313)

      82,706








      HLS THERAPEUTICS INC.

      INTERIM CONSOLIDATED STATEMENTS OF CASH FLOWS

      Unaudited

      [in thousands of U.S. dollars]




      Three months ended

      June 30,

      Six months ended

      June 30,


      2025

      2024

      2025

      2024






      OPERATING ACTIVITIES





      Net loss for the period

      (2,741)

      (5,682)

      (7,177)

      (11,788)

      Adjustments to reconcile net loss to cash provided

         by operating activities





      Stock-based compensation

      465

      427

      1,116

      683

      Amortization and depreciation

      5,483

      5,856

      10,843

      11,775

      Gain on royalty sale

      —

      (3,381)

      —

      (3,381)

      Accreted interest expense

      302

      277

      610

      559

      Fair value adjustment on financial assets and liabilities

      —

      318

      —

      505

      Deferred income taxes

      (189)

      3,861

      (478)

      3,800

      Net change in non-cash working capital balances related to

         operations

      1,284

      843

      3,233

      1,144

      Cash provided by operating activities

      4,604

      2,519

      8,147

      3,297






      INVESTING ACTIVITIES





      Intangible asset acquisition

      (1,000)

      —

      (1,000)

      —

      Additions to property, plant and equipment

      (87)

      —

      (108)

      (2)

      Proceeds from royalty sale

      —

      13,250

      —

      13,250

      Cash provided by (used in) investing activities

      (1,087)

      13,250

      (1,108)

      13,248






      FINANCING ACTIVITIES





      Shares repurchased

      (833)

      (317)

      (1,009)

      (600)

      Repayment of credit agreement borrowing

      (8,481)

      (1,493)

      (11,441)

      (3,568)

      Debt costs

      —

      (658)

      —

      (1,191)

      Lease payments

      (151)

      (112)

      (294)

      (255)

      Cash used in financing activities

      (9,465)

      (2,580)

      (12,744)

      (5,614)






      Net increase (decrease) in cash during the period

      (5,948)

      13,189

      (5,705)

      10,931

      Foreign currency translation

      367

      (117)

      402

      (368)

      Cash, beginning of period

      17,734

      19,443

      17,456

      21,952

      Cash, end of period

      12,153

      32,515

      12,153

      32,515




      SOURCE HLS Therapeutics Inc.

      HLS CONTACT INFORMATION: Dave Mason, Investor Relations, HLS Therapeutics Inc., (416) 247-9652, [email protected]

      Modal title

      Organization Profile

      HLS Therapeutics Inc.

        Also from this source

      • HLS Therapeutics Announces Q3 2026 Financial Results

      • HLS Therapeutics Partners with Bayer to Commercialize VERQUVO® in Canada

      • HLS Therapeutics to Host Q3 2026 Financial Results Conference Call

      Contact PR Newswire

      • 866-245-2317
        from 7:30 AM - 6:30 PM ET
      • Become a Client
      • Request a Demo
      • Editorial Bureaus
      • Partnerships
      • General Enquiries
      • Media

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • Investor Relations

      About

      • About PR Newswire
      • About Cision
      • Careers
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United States
      • Vietnam

      My Services

      • All News Releases
      • Platform Login
      • Privacy Policy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact Cision

      Products

      About

      My Services
      • All News Releases
      • Platform
      • Next Gen Communications Cloud
      • Cision Communications Cloud
      • my CNW
      877-269-7890
      from 8 AM - 10 PM ET
      • Terms of Use
      • Information Security Policy
      • Site Map
      • Cookie Settings
      • Accessibility Statement
      Copyright © 2026 CNW Group Ltd. All Rights Reserved. A Cision company.